MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Stroke Ischemic
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Masking Description: Blinded endpoint assessment by independent CECPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible patients will be randomly assigned to either the control (antiplatelet) or the experimental (DOAC) arm with a ratio of 1:1....
Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible patients will be randomly assigned to either the control (antiplatelet) or the experimental (DOAC) arm with a ratio of 1:1. Each study participant will be observed during a follow up period within one year after index stroke.
Tracking Information
- NCT #
- NCT03961334
- Collaborators
- Swiss National Science Foundation
- Investigators
- Principal Investigator: Mira Katan, PD Dr. med. University of Zurich
Get Well Soon